Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 0.95 USD 3.64% Market Closed
Market Cap: 265.3m USD
Have any thoughts about
Lyell Immunopharma Inc?
Write Note

Lyell Immunopharma Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lyell Immunopharma Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Lyell Immunopharma Inc
NASDAQ:LYEL
Net Income (Common)
-$234.6m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Lyell Immunopharma Inc
Glance View

Market Cap
243.7m USD
Industry
Biotechnology

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

LYEL Intrinsic Value
0.72 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Lyell Immunopharma Inc's Net Income (Common)?
Net Income (Common)
-234.6m USD

Based on the financial report for Dec 31, 2023, Lyell Immunopharma Inc's Net Income (Common) amounts to -234.6m USD.

What is Lyell Immunopharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-5%

Over the last year, the Net Income (Common) growth was -28%. The average annual Net Income (Common) growth rates for Lyell Immunopharma Inc have been -5% over the past three years .

Back to Top